Scoop has an Ethical Paywall
Scoop InfoPages
This InfoPage in unregistered, if this is your news page register Eli Lilly And Company for InfoPages here.
Eli Lilly And Company - Latest News [Page 1]
Improved Access To Diabetes Medicine
Friday, 30 March 2007, 4:31 pm | Eli Lilly And Company
Changes to Special Authority criteria extend the patient group eligible for subsidy and reduce wait for treatment. More >>
Diabetes drug access widened
Monday, 1 August 2005, 3:26 pm | Eli Lilly And Company
Auckland, 1 August 2005 – Access to type 2 diabetes medicine Actos (pioglitazone) is to be significantly widened in a new agreement between PHARMAC and Eli Lilly. The original access criteria implemented a year ago have proven difficult to meet ... More >>
Funding brings hope for 3000 diabetes patient
Wednesday, 25 August 2004, 1:25 pm | Eli Lilly And Company
Auckland, 25 August 2004 – An innovative medicine for type 2 diabetes is to be funded by PHARMAC for the first time in New Zealand from 1st September 2004. Actos is the first oral medication for type 2 diabetes to be funded for around 10 years and tackles ... More >>
First Treatment for Asbestos-Related Lung Cancer
Monday, 23 August 2004, 10:22 am | Eli Lilly And Company
Auckland – The first and only oncology treatment for asbestos-related lung cancer, malignant pleural mesothelioma (MPM), has been registered for use in New Zealand and is now available1. Alimta (Pemetrexed) has been shown to extend the life expectancy ... More >>
New funding for bi-polar disorder
Thursday, 5 August 2004, 2:26 pm | Eli Lilly And Company
Auckland 5th August 2004 – A new agreement between Eli Lilly and Company NZ and PHARMAC guarantees long-term supply and improved patient access to leading anti-psychotic medicine Zyprexa (Olanzapine) from September 1st 2004 More >>
Cialis captures just under half of NZ market
Monday, 14 July 2003, 3:10 pm | Eli Lilly And Company
In its first few months in New Zealand, the second generation treatment for erection problems, Cialis, captured just under half of the erectile dysfunction market. More >>
